Table 1 Studies evaluating altered miRNA expression in women with and without PCOS
From: Non-coding RNAs in polycystic ovary syndrome: a systematic review and meta-analysis
Study | Detected in tissue/cell | No. of PCOS and control | Age of PCOS/ control (years) | BMI of PCOS/ control (m/kg2) | Dysregulated miRNAs |
|---|---|---|---|---|---|
Murri et al. 2013 [15] | Whole blood | 12 PCOS vs 12 healthy controls woman vs 12 healthy men | Lean: 27 ± 4/29 ± 3 Obese: 27 ± 2/29 ± 7 | Lean: 22 ± 2/22 ± 2 Obese: 39 ± 9/27 ± 6 | Upregulated: miR-21,27b, 103 and 155 |
Long et al. 2014 [24] | Serum | 68 PCOS vs 68 controls | 26.6 ± 2.8/27.9 ± 3.4 | 25.9 ± 3.4/22.4 ± 2.1 | Upregulated: miR-222, 146a and 30c |
Liyan Jiang et al. 2015 [31] | Serum | 30 PCOS vs 30 controls | 27.5 ± 3.2/28.1 ± 4.1 | 25.8 ± 2.1/22.3 ± 1.5 | Upregulated: miR21,222,16,19a,30c, 146a, 24 and 186 |
Ding et al. 2015 [30] | Serum | 18 PCOS vs 18 controls | 28.3 ± 5.6/29.1 ± 4.8 | 31.5 ± 4.1/22.7 ± 3.2 | Upregulated: miR-5706, let-7i-3 pm, 4463, 3665 and 638 Downregulated: miR-124-3p, 128, 29a-3p and let-7c |
Sathyapalan et al. 2015 [32] | Plasma | 25 PCOS vs 25 controls | 32.1 ± 9/32.2 ± 7.7 | 28.8 ± 5.4/27.1 ± 5.8 | Upregulated: miR-93 and 223 |
Song et al. 2015 [33] | Serum | 67 PCOS vs 67 controls | 26.7 ± 2.7/27.6 ± 3.3 | 24.8 ± 3.3/21.9 ± 2.2 | Downregulated: miR-592,124-3p, 128, 29-3p, 16, 106b, 19a, 24, 186, let-7c and 1228 |
Zhao et al. 2015 [34] | Serum | 30 PCOS vs 70 controls | 27.70 ± 3.44/27.93 ± 3.84 | 24.39 ± 3.67/21.87 ± 2.93 | Upregulated: miR-146a, 30c and 191 Downregulated: miR-16, 223, 212, 451 and 92a |
Song et al. 2016 [36] | Serum | 21 PCOS vs 21 controls | 23 ± 4/24 ± 6 | 21.7 ± 2.3/ 22.2 ± 2.7 | Downregulated: miR-4522, 324-3p, and 6767-5p |
Jiang et al. 2016 [35] | Serum | 30 PCOS vs 30 controls | 27.16 ± 3.56/27.98 ± 3.66 | 22.24 ± 3.87/20.46 ± 2.44 | Upregulated: miR-122, 194, and 193b Downregulated: miR-199b-5p |
Xiong et al. 2017 [39] | Serum | 18 PCOS vs 30 controls | 25.8 ± 4.5/25.5 ± 2.3 | 23.96 ± 4.44/20.99 ± 3.31 | Downregulated: miR-23a and 23b |
Hosseini et al. 2017 [38] | Plasma | 205 PCOS vs 205 controls | 31.2 ± 5.5/28.5 ± 5 | 26.5 ± 5/25.1 ± 4.6 | Upregulated: miR-146a and 222 |
Eisenberg et al. 2017 [37] | Serum | 18 PCOS vs 15 controls | 26.9 ± 4.3/26.8 ± 4.7 | 29.3 ± 7.1/23.6 ± 3.3 | Upregulated: miR-200b and 429 |
Ebrahimi et al. 2018 [40] | Whole blood | 180 PCOS vs 192 controls | 26.8 ± 5.5/27.0 ± 4.38 | 23.3 ± 3.6/22.92 ± 2.86 | Upregulated: miR-146a |
Naji et al. 2018 [42] | Serum, granulosa-lutein cells, follicular fluid | 20 PCOS vs 21 controls | 29.25 ± 0.84/28.42 ± 0.91 | 26.48 ± 0.85/24.58 ± 0.85 | Upregulated in follicular fluid: miR-182 Downregulated in granulosa-lutein cells: miR-145 and 182 |
Murri et al. 2018 [41] | Serum | 12 PCOS vs 11 controls | Lean: 27 ± 4/28 ± 3 Obese: 27 ± 2/31 ± 6 | Lean: 22 ± 2/22 ± 2 Obese: 39 ± 9/37 ± 3 | Upregulated: miR-34c-5p and 548d-3p Downregulated: miR-26a-5p, 30c-5p, 107 and 199a-3p |
Nanda et al. 2019 [43] | Serum | 20 PCOS vs 20 controls | 28.35 ± 7.45/25.15 ± 4.12 | 32.16 ± 4.93/22.02 ± 2.64 | Upregulated: miR-122, 194, and 193b Downregulated: miR-199b-5p |
Rashad et al. 2019 [44] | Serum | 60 PCOS vs 40 controls | 31.95 ± 7.42/32.38 ± 7.68 | 33.2 ± 5.73/24.9 ± 2.48 | Downregulated: miR-320 |
Sang et al. 2013 [25] | Follicular fluid | 24 PCOS vs 24 controls | 29.09 ± 0.70/30.83 ± 0.90 | 23.38 ± 0.59/21.95 ± 0.51 | Downregulated: miR-132 and 320 |
Roth et al. 2014 [45] | Follicular fluid | 12 PCOS vs 12 controls | 33.1 ± 4.4/27.1 ± 3.6 | 25.6 ± 6.3/23.8 ± 2.9 | Upregulated: miR-32, 34c, 135a, 18b, and 9 |
Yin et al. 2014 [46] | Follicular fluid, granulosa cells | 19 PCOS vs 15 controls | 20–40/20–40 | NA/NA | Upregulated: miR-320 and miR-383 |
Scalici et al. 2016 [47] | Follicular fluid | 30 PCOS vs 91 controls | 33.1 ± 3.8/34.3 ± 5.1 | 25.4 ± 5.3/ 22.8 ± 3.7 | Upregulated: miR-30a Downregulated: miR-140 and let-7b |
Sorensen et al. 2016 [48] | Follicular fluid | 49 PCOS vs 21 controls | 28.1 ± 4.3/ 27.8 ± 3.8 | 25.7 ± 5.1/ 24.2 ± 3.8 | Upregulated: miR-518f-3p Downregulated: miR-24–3p, 29a, 151–3p and 574–3p |
Naji et al. 2017 [49] | Follicular fluid, granulosa cells | 19 Hyper-androgenic PCOS vs 22 normo-androgenic PCOS | 29 ± 0.66/ 28.89 ± 1.07 | 27.02 ± 0.97/25.94 ± 0.75 | Upregulated in granulosa cells: miR-93 Downregulated in follicular fluid: miR-93 and 21 |
Xue et al. 2018 [50] | Follicular fluid | 3 PCOS vs 3 controls | 29, 36, 38/30, 31, 36 | 21.51,22.13,20.22/ 21.86,21.14, 20.94 | Upregulated: miR-200a-3p, 10b-3p, 200b-3p,29c-3p, 99a-3p and 125a-5p Downregulated: miR-105-3p |
Yao et al. 2018 [51] | Follicular fluid | 55 PCOS vs 51 controls | 28.13 ± 0.41/ 27.37 ± 0.46 | 23.25 ± 0.45/ 21.62 ± 0.38 | Downregulated: miR-335-5p |
Zhang et al. 2018 [52] | Follicular fluid | 20 PCOS vs 20 controls | NA/ NA | NA/ NA | Upregulated: miR-873-5p |
Linlin Jiang et al. 2015 [27] | Granulosa cells | 16 PCOS vs 8 controls | 29.69 ± 2.39/ 31.75 ± 4.40 | 24.07 ± 5.33/21.17 ± 3.06 | Upregulated: miR-93, 107 |
Shi et al. 2015 [53] | Cumulus cells | 24 PCOS vs 24 controls | 28.3 ± 3.3/ 28.5 ± 3.6 | 21.5 ± 2.5/20.7 ± 2.1 | Downregulated: miR-483–5p and 486–5p |
Liu et al. 2015 [54] | Cumulus cells | 10 PCOS vs 10 controls | 27.4 ± 2.6/ 29.4 ± 3.0 | 22.0 ± 3.5/ 23.5 ± 3.2 | Upregulated: miR-513a-3p, 508-3p, 513b, 514, 509-5p, 513c, 144, 510, 509-3p and 508-5p Downregulated: miR-151-3p, 720, 615-3p, 127-3p, 455-3p, 342-3p and 654-3p |
Xu et al. 2015 [55] | Cumulus granulosa cells | 21 PCOS vs 20 controls | 28.76 ± 3.51/ 29.43 ± 3.92 | 24.01 ± 3.39/21.68 ± 2.99 | Upregulated: miR-423-3p, 3651, 3653, 151b, 1273 g-3p, 590-5p, 3648, 7845-5p, 27a-5p, 1275, 483-3p, 7-5p, 483-5p, 10a-5p, 184, 619-5p, 513b-5p, 1307-5p, 4516, 1307-3p, 514b-5p Downregulated: miR-3529-3p, 7974, 3065-5p, 214-3p, 200a-3p, 203a, 4732-5p, 423-5p, 3184-5p, 548n, 221-3p, 149-5p, 1298-5p, 193a-3p, 365a-3p, 219a-1-3p, 550b-2-5p, 144-5p, 660-5p, 548e-3p, 652-3p, 222-3p,506-5p, 193a-5p, 210-5p, 365b-5p, 330-3p, 223-3p, 186-5p, 185-5p, 92b-3p, 199b-3p, 766-5p, 15b-3p, 339-5p, 3960, 766-3p, let-7a-3p |
Study | Detected in tissue/cell | No. of PCOS and control | Age of PCOS/ control (years) | BMI of PCOS/ control (m/kg2) | Dysregulated miRNAs |
Huang et al. 2016 [56] | Cumulus cells | 18 PCOS vs 18 controls | 32.6 ± 3.1/ 34.6 ± 2.2 | 21.6 ± 1.5/ 21.4 ± 1.8 | Upregulated: miR-135b-5p, 152, 193a-3p, 194-5p, 196a-5p, 200b-3p, 423-3p, 454-3p, 455-5p, 4659a-3p, 509–3-5p, 509-3p, 513b-5p, 652-5p, 95, 1273e |
Cai et al. 2017 [57] | Granulosa cells | 25 PCOS vs 25 controls | 29 ± 3.5/ 29 ± 3.5 | NA/ NA | Downregulated: miR-145 |
Zhang et al. 2017 [58] | Cumulus cells | 21 PCOS vs 12 controls | 28.7 ± 2.6/ 29.4 ± 3.1 | 21.4 ± 3.3/22.7 ± 2.9 | Downregulated: miR-320a |
He et al. 2018 [59] | Granulosa cells | 62 PCOS vs 61 controls | 28.27 ± 3.10/ 28.71 ± 2.46 | 24.40 ± 3.34/21.77 ± 2.37 | Downregulated: miR-141 and 200c |
Mao et al. 2018 [60] | Granulosa cells | 43 PCOS vs 26 controls | 30.2 ± 2.8/ 31.1 ± 2.1 | 23.2 ± 1.7/22.1 ± 1.6 | Downregulated: miR-126-5p and 29a-5p |
Wang et al. 2018 [61] | Granulosa cells | 21 PCOS vs 13 controls | 28.67 ± 3.70/ 30.00 ± 2.77 | 24.69 ± 1.19/23.63 ± 1.70 | Upregulated: miR-27a-3p |
Zhong et al. 2018 [62] | Granulosa cells, ovarian cortex | 18 PCOS vs 10 controls | NA/ NA | NA/ NA | Downregulated: miR-19b |
Geng et al. 2019 [63] | Granulosa cells | 15 PCOS vs 15 controls | 27.23 ± 1.83/ 28.53 ± 1.85 | 22.17 ± 2.04/21.79 ± 2.13 | Upregulated: miR-99a |
Li et al. 2019 [64] | Granulosa cells | 46 PCOS vs 32 controls | 29.21 ± 4.78/ 29.43 ± 3.82 | 24.35 ± 3.32/23.12 ± 2.13 | Upregulated: miR-33b and 142 Downregulated: miR-423 |
Luo et al. 2019 [65] | Granulosa cells | 20 PCOS vs 18 controls | 27 ± 3.26/ 29 ± 3.22 | NA/ NA | Upregulated: miR-23a |
Wang et al. 2019 [66] | Granulosa cells | 24 PCOS vs 21 controls | 28.708 ± 0.802/29.571 ± 0.994 | 25.958 ± 0.836/22.173 ± 0.878 | Upregulated: miR-3188 and 3135b |
Song et al. 2019 [67] | Granulosa cells | 63 PCOS vs 20 controls | 28.21 ± 2.78/ 27.43 ± 3.62 | 24.35 ± 2.12/22.12 ± 1.73 | Upregulated: miR-186 and 135a |
Hou et al. 2019 [68] | Granulosa cells | 38 PCOS vs 35 controls | 29.60 ± 0.66/ 29.66 ± 0.82 | 25.25 ± 0.59/22.63 ± 0.53 | Upregulated: miR-3188 and 3135b |
McCallie et al. 2010 [69] | Blastocysts | 6 PCOS vs 10 controls | NA/ NA | NA/ NA | Downregulated: miR- let-7a, 19a, 19b, 24, 92, and 93 |
Chen et al. 2013 [26] | Adipose tissue | 11 PCOS vs 11 controls | 27.46 ± 4.07/ 32.41 ± 6.61 | 28.56 ± 5.6/ 22.89 ± 2.65 | Upregulated: miR-93, 133 and 223 |
Wu et al. 2014 [70] | Adipose tissue | 8 PCOS with IR vs 8 PCOS without IR vs 9 controls with IR vs 6 healthy without IR | 27.75 ± 4.98/ 30.00 ± 5.57/ 33.66 ± 6.37/ 32.33 ± 5.03 | 31.92 ± 4.95/25.49 ± 5.56/35.78 ± 7.68/22.80 ± 1.32 | Upregulated in PCOS patients and controls with IR: miR-93, and 25 |
Lin et al. 2015 [17] | Ovarian theca interna tissues | 10 PCOS vs 8 controls | 28.80 ± 3.97/ 32.00 ± 2.16 | 24.42 ± 4.84/20.51 ± 2.06 | Downregulated: miR-19b, 92a, 92b, 141, and 200a |
Xiang et al. 2016 [71] | Ovary cortex | 20 PCOS vs 20 controls | 27.3 ± 2.5/ 28.2 ± 3.7 | 26.2 ± 3.7/ 22.0 ± 2.5 | Downregulated: miR-483 |
Yuan et al. 2017 [72] | Ovarian tissue | 20 PCOS vs 20 controls | NA/ NA | NA/ NA | Downregulated: miR-320 |
McAllister et al. 2019 [73] | Ovarian theca cells | 7 PCOS vs 7 controls | NA/ NA | NA/ NA | Upregulated: miR-100-5p, 99b-5p, 1271-5p, 409-5p, 744, 410-3p, 127-3p, 654-5p, 494-3p, 1301-3p, 502-3p, 501-3p and 1293 Downregulated: miR-125a-3p,148b-5p, 195-5p,130b-3p and 4542a-5p |